Efficacy and safety of ticagrelor combined with emergency percutaneous coronary intervention in the treatment of acute myocardial infarction
AIM To observe the effect of ticagrelor combined with emergency percutaneous coronary intervention(PCI)in the treatment of acute myocardial infarction(AMI).METHODS A total of 127 patients with acute myocardial infarction who underwent emergency PCI treatment in our hospital from March 2021 to June 2022 were selected for experimental observation,and the patients were randomly divided into control group(63 patients)and experimental group(64 patients).The patients in the 2 groups received antiplatelet therapy with clopidogrel and ticagrelor respectively during the preoperative stage.The platelet aggregation function,myocardial function and blood flow after antiplatelet therapy and the occurrence of bleeding events were compared between 2 groups.RESULTS The levels of creatine kinase-MB(CK-MB)and cardiac troponin I(CTnI)at 10 min and 24 h after PCI in the experimental group were significantly lower than those in the control group(P＜0.05).The platelet inhibition index of the ADP pathway in the experimental group was significantly higher than that in the control group,and the maximum platelet aggregation index and P2Y12 response unit were significantly lower than those in the control group(P＜0.05).After treatment,the distribution in grade of thrombolysis in myocardial infarction(TIMI)and TIMI myocardial perfusion(TMP)on the day after operation between 2 groups was significantly confident(P＜0.05).The left ventricular ejection fraction in the experimental group was significantly higher than that in the control group,and the left ventricular end-diastolic diameter was significantly lower than that in the control group(P＜0.05).There was no significant difference in the incidence of bleeding events between 2 groups during treatment(P＞0.05).CONCLUSION The inhibitory effect of ticagrelor on platelet aggregation is significantly better than that of clopidogrel.Combined with emergency PCI in the treatment of acute myocardial infarction,ticagrelor can effectively improve the degree of perioperative myocardial injury,improve myocardial blood perfusion,enhance cardiac systolic function,and dose not increase the risk of adverse events.
国家科技期刊平台
NSTL
万方数据
